Drugs / NNC0174-1213
last change May 2026 re-read 2 minutes ago

NNC0174-1213

Developed for
obesity disorder
Investigated by
Novo Nordisk A/S

Trials 1 · a red edge is where a trial was stopped

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06719011 Dec 2024 → Mar 2026 overdue obesity disorder Novo Nordisk A/S Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NNC0174-1213 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06719011
Route Subcutaneous “administered as subcutaneous (s.c. under the skin) injection” NCT06719011